

Form 62-103F1

Required Disclosure under the Early Warning Requirements

State if this report is filed to amend information disclosed in an earlier report. Indicate the date of the report that is being amended.

This report is filed by Knight Therapeutics Inc. (“Knight”) to amend the information disclosed in the report dated March 13, 2018.

Item 1 – Security and Reporting Issuer

1.1 State the designation of securities to which this report relates and the name and address of the head office of the issuer of the securities.

Common shares (the “Shares”) of Crescita Therapeutics Inc. (“Crescita”).
Crescita’s head office address is located at:

2805 Place Louis-R-Renaud
Laval, Québec
H7V 0A3

1.2 State the name of the market in which the transaction or other occurrence that triggered the requirement to file this report took place.

Disposal of shares: Toronto Stock Exchange

Item 2 – Identity of the Acquiror

2.1 State the name and address of the acquiror.

Knight Therapeutics Inc.
3400 De Maisonneuve Blvd. W.
Suite 1055
Montreal, Quebec
H3Z 3B8

Jurisdiction of incorporation: Canada

Principal business: Consumer products – Biotechnology/Pharmaceuticals

2.2 State the date of the transaction or other occurrence that triggered the requirement to file this report and briefly describe the transaction or other occurrence.

Since July 15, 2019, Knight disposed of an aggregate of 879,200 Shares of Crescita on the Toronto Stock Exchange at an average price of \$1.02 per share for total gross proceeds of \$894,750.

2.3 State the names of any joint actors.

Not applicable

Item 3 – Interest in Securities of the Reporting Issuer

3.1 State the designation and number or principal amount of securities acquired or disposed of that triggered the requirement to file this report and the change in the acquiror’s securityholding percentage in the class of securities.

Knight disposed of an aggregate of 879,200 Shares, representing approximately 4.1% of Shares outstanding, after giving effect to the 396,000 Shares to be issued should Knight exercise the Warrants.

3.2 State whether the acquiror acquired or disposed ownership of, or acquired or ceased to have control over, the securities that triggered the requirement to file this report.

Knight disposed ownership of 879,200 Shares.

3.3 If the transaction involved a securities lending arrangement, state that fact.

Not applicable

3.4 State the designation and number or principal amount of securities and the acquiror’s security holding percentage in the class of securities, immediately before and after the transaction or other occurrence that triggered the requirement to file this report.

Prior to the dispositions, Knight owned an aggregate of 2,834,689 Shares representing approximately 13.5% of the outstanding Shares and 396,000 common share purchase warrants of Crescita (the “Warrants”). Had Knight exercised the Warrants in full, it would have acquired an additional 396,000 Shares, representing a combined holding of approximately 15.1% of the Shares outstanding, after giving effect to the exercise of the Warrants held by Knight only. Immediately after the sale of 879,200 Shares of Crescita, Knight owns 1,955,489 Shares representing approximately 9.3% of the Shares outstanding, as well as 396,000 Warrants. Should Knight exercise the Warrants, it would acquire an additional 396,000 Shares of Crescita, representing combined holdings of approximately 11.0% of the outstanding Shares, assuming the exercise of Warrants by Knight only.

3.5 State the designation and number or principal amount of securities and the acquiror’s security holding percentage in the class of securities referred to in Item 3.4 over which

(a) the acquiror, either alone or together with any joint actors, has ownership and control,

As of the date of this report, Knight owns 1,955,489 Shares and 396,000 Warrants, representing approximately 11.0% of the outstanding Shares, assuming the exercise of Warrants by Knight only.

- (b) **the acquiror, either alone or together with any joint actors, has ownership but control is held by persons or companies other than the acquiror or any joint actor, and**

Not applicable

- (c) **the acquiror, either alone or together with any joint actors, has exclusive or shared control but does not have ownership.**

Not applicable

- 3.6 If the acquiror or any of its joint actors has an interest in, or right or obligation associated with, a related financial instrument involving a security of the class of securities in respect of which disclosure is required under this item, describe the material terms of the related financial instrument and its impact on the acquiror's security holdings.**

Not applicable

- 3.7 If the acquiror or any of its joint actors is a party to a securities lending arrangement involving a security of the class of securities in respect of which disclosure is required under this item, describe the material terms of the arrangement including the duration of the arrangement, the number or principal amount of securities involved and any right to recall the securities or identical securities that have been transferred or lent under the arrangement.**

Not applicable

- 3.8 If the acquiror or any of its joint actors is a party to an agreement, arrangement or understanding that has the effect of altering, directly or indirectly, the acquiror's economic exposure to the security of the class of securities to which this report relates, describe the material terms of the agreement, arrangement or understanding.**

Not applicable

Item 4 – Consideration Paid

- 4.1 State the value, in Canadian dollars, of any consideration paid or received per security and in total.**

Knight received a consideration of an average \$1.02 per Share or \$894,750 in connection with the sale of 879,200 Shares.

- 4.2 In the case of a transaction or other occurrence that did not take place on a stock exchange or other market that represents a published market for the securities, including an issuance from treasury, disclose the nature and value, in Canadian dollars, of the consideration paid or received by the acquiror.**

Not applicable

4.3 If the securities were acquired or disposed of other than by purchase or sale, describe the method of acquisition or disposition.

Not applicable

Item 5 – Purpose of the Transaction

State the purpose or purposes of the acquiror and any joint actors for the acquisition or disposition of securities of the reporting issuer. Describe any plans or future intentions which the acquiror and any joint actors may have which relate to or would result in any of the following:

- (a) the acquisition of additional securities of the reporting issuer, or the disposition of securities of the reporting issuer;**
- (b) a corporate transaction, such as a merger, reorganization or liquidation, involving the reporting issuer or any of its subsidiaries;**
- (c) a sale or transfer of a material amount of the assets of the reporting issuer or any of its subsidiaries;**
- (d) a change in the board of directors or management of the reporting issuer, including any plans or intentions to change the number or term of directors or to fill any existing vacancy on the board;**
- (e) a material change in the present capitalization or dividend policy of the reporting issuer;**
- (f) a material change in the reporting issuer’s business or corporate structure;**
- (g) a change in the reporting issuer’s charter, bylaws or similar instruments or another action which might impede the acquisition of control of the reporting issuer by any person or company;**
- (h) a class of securities of the reporting issuer being delisted from, or ceasing to be authorized to be quoted on, a marketplace;**
- (i) the issuer ceasing to be a reporting issuer in any jurisdiction of Canada;**
- (j) a solicitation of proxies from securityholders;**
- (k) an action similar to any of those enumerated above.**

Knight disposed of the Shares for investment purposes. Except as described herein, while Knight has no current plans or intentions that relate to or would result in the items listed in (a) through (k) above, depending on various factors including, without limitation, Crescita’s financial position, the price levels of the Shares, conditions in the securities markets and general economic and industry

conditions, Crescita's business or financial condition, and other factors and conditions Knight deems appropriate, Knight may develop such plans in future.

Item 6 – Agreements, Arrangements, Commitments or Understandings With Respect to Securities of the Reporting Issuer

Describe the material terms of any agreements, arrangements, commitments or understandings between the acquiror and a joint actor and among those persons and any person with respect to securities of the class of securities to which this report relates, including but not limited to the transfer or the voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, guarantees of profits, division of profits or loss, or the giving or withholding of proxies. Include such information for any of the securities that are pledged or otherwise subject to a contingency, the occurrence of which would give another person voting power or investment power over such securities, except that disclosure of standard default and similar provisions contained in loan agreements need not be included.

Not applicable

Item 7 – Change in Material Fact

If applicable, describe any change in a material fact set out in a previous report filed by the acquiror under the early warning requirements or Part 4 in respect of the reporting issuer's securities.

This report is filed by Knight to amend the information disclosed in the report dated March 13, 2018.

Item 8 – Exemption

If the acquiror relies on an exemption from requirements in securities legislation applicable to formal bids for the transaction, state the exemption being relied on and describe the facts supporting that reliance.

Not applicable

Item 9 – Certification

The acquiror must certify that the information in this report is true and complete in every respect. In the case of an agent, the certification is based on the agent's best knowledge, information and belief but the acquiror is still responsible for ensuring that the information filed by the agent is true and complete.

This report must be signed by each person on whose behalf the report is filed or his or her authorized representative.

It is an offence to submit information that, in a material respect and at the time and in the light of the circumstances in which it is submitted, is misleading or untrue.

Certificate

“I, as the acquiror, certify, to the best of my knowledge, information and belief, that the statements made in this report are true and complete in every respect.”

August 6, 2019

Knight Therapeutics Inc.

Per: (signed) Samira Sakhia
Name: Samira Sakhia
Title: President & Chief Financial Officer